Altimmune Inc (ALT)

$3.53 -0.10 (-2.75%)
Market Cap 319.49M
Revenue (ttm) 20,000.00
Net Income (ttm) -95.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475,300.00%
Debt to Equity Ratio 0.09
Volume 1,913,900
Avg Vol 6,502,120
Day's Range N/A - N/A
Shares Out 88.26M
Stochastic %K 34%
Beta -0.01
Analysts Strong Sell
Price Target $18.44

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
Drewpac
Drewpac Aug. 22 at 4:42 AM
$ALT Hi Patrick! Or should I say Bio 🥜?????
0 · Reply
Drewpac
Drewpac Aug. 22 at 4:41 AM
$ALT I got nothing to share other than I'm on the midnight train to poundtown. First stop... The 🥒 gobbler. It's gonna get nasty...
0 · Reply
BioRich
BioRich Aug. 22 at 4:33 AM
$ALT In all seriousness, what in $ALT's 48W data would take more than a week to compile, review and present? I don't see anything other than more time to try and massage data. The numbers are all in, compiled and (I believe) available for $ALT review.
1 · Reply
BioRich
BioRich Aug. 22 at 4:29 AM
$ALT Since this $ALT board seems infatuated with $VKTX and crapping all over it after its recent SP drop, can any of you explain why the SP dropped? Have any of you actually reviewed the data or just the headlines? Curious.
1 · Reply
Excessive_
Excessive_ Aug. 22 at 4:17 AM
$ALT When I see a chart like this, I get happiness thinking of the possibility that perhaps the short that is putting in all the work to push it down. Isn't the one that is doing the buying or covering at the bottom 😁 It's actually not bad, considering nearly the whole market has been crashing all week. Let's hear some good news tomorrow.
1 · Reply
Drewpac
Drewpac Aug. 22 at 4:09 AM
$ALT
0 · Reply
dachshund36
dachshund36 Aug. 22 at 3:45 AM
$ALT Could be a huge boost. We shouldn't even need a little boost, but here it is https://www.snopes.com/fact-check/ozempic-2-billion-lawsuit/
1 · Reply
ImNotLion
ImNotLion Aug. 22 at 2:58 AM
$ALT Ozempic going down in flames. 2 Billion dollar lawsuit. 1800 permanently blinded?
5 · Reply
BTECHINV
BTECHINV Aug. 22 at 2:12 AM
$ALT $XBI The higher the dose of GLP-1 and GIP, the more that stomach motility / gastric emptying is potentially impacted. Far better mechanism for a variety of reasons imo to induce thermogenic and energy expenditure metabolic effects (potent GCGR w modest GLP1 dosing). 99%+ of people have no idea about the above. The minute they realize the significance, a new global paradigm will emerge in the cultural zeitgeist. You can already imagine the articles. $NVO $PFE Disclosure: Long Altimmune (Pemvi GCGR), not medical / investment advice.
1 · Reply
Stock_Catcher
Stock_Catcher Aug. 22 at 2:06 AM
Fortune Friday Watchlist Pt. 5 $GALT $ALT $PGEN $MBOT $BSLK Squeeze Time? 🍋
1 · Reply
Latest News on ALT
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Aug 19, 2025, 7:30 AM EDT - 2 days ago

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Aug 18, 2025, 8:45 AM EDT - 3 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Aug 15, 2025, 12:06 PM EDT - 6 days ago

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:44 PM EDT - 8 days ago

Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Aug 13, 2025, 2:57 PM EDT - 8 days ago

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

Aug 12, 2025, 7:00 AM EDT - 9 days ago

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

Altimmune Board of Directors Appoints Jerry Durso as Chairman

Aug 11, 2025, 7:30 AM EDT - 10 days ago

Altimmune Board of Directors Appoints Jerry Durso as Chairman

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Aug 5, 2025, 7:30 AM EDT - 16 days ago

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm

Jul 19, 2025, 2:30 PM EDT - 4 weeks ago

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

Jul 9, 2025, 7:30 AM EDT - 6 weeks ago

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

Jun 27, 2025, 2:39 PM EDT - 7 weeks ago

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

Altimmune: Deciphering The MASH Crash (Rating Upgrade)

Jun 26, 2025, 4:30 PM EDT - 2 months ago

Altimmune: Deciphering The MASH Crash (Rating Upgrade)

Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide

Jun 26, 2025, 2:59 PM EDT - 2 months ago

Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide

Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Jun 26, 2025, 8:16 AM EDT - 2 months ago

Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

BTBT KTOS

Altimmune's weight-loss drug meets main goal in fatty liver disease trial

Jun 26, 2025, 7:43 AM EDT - 2 months ago

Altimmune's weight-loss drug meets main goal in fatty liver disease trial

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

Jun 26, 2025, 7:00 AM EDT - 2 months ago

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

Jun 25, 2025, 7:12 PM EDT - 2 months ago

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions

Jun 13, 2025, 7:30 AM EDT - 2 months ago

Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions

Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential

Jun 2, 2025, 10:51 AM EDT - 2 months ago

Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential

VKTX

Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity

May 29, 2025, 10:25 AM EDT - 3 months ago

Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

May 19, 2025, 7:30 AM EDT - 3 months ago

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

Altimmune to Participate at Two Upcoming Investor Conferences

May 14, 2025, 7:30 AM EDT - 3 months ago

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript

May 13, 2025, 2:57 PM EDT - 3 months ago

Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript

Altimmune Announces First Quarter 2025 Financial Results and Business Update

May 13, 2025, 7:00 AM EDT - 3 months ago

Altimmune Announces First Quarter 2025 Financial Results and Business Update

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

May 13, 2025, 7:00 AM EDT - 3 months ago

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

HTGC

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

May 8, 2025, 7:30 AM EDT - 3 months ago

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

May 6, 2025, 7:30 AM EDT - 3 months ago

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

May 1, 2025, 7:30 AM EDT - 4 months ago

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

Altimmune to Participate in the Citizens Life Sciences Conference

Apr 30, 2025, 7:30 AM EDT - 4 months ago

Altimmune to Participate in the Citizens Life Sciences Conference

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Mar 17, 2025, 3:21 PM EDT - 5 months ago

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Altimmune to test obesity drug for alcohol use disorder and related health conditions

Mar 13, 2025, 5:26 PM EDT - 5 months ago

Altimmune to test obesity drug for alcohol use disorder and related health conditions

Altimmune to Host Virtual R&D Day on March 13, 2025

Mar 6, 2025, 7:30 AM EST - 6 months ago

Altimmune to Host Virtual R&D Day on March 13, 2025

Altimmune to Participate in the Leerink Global Healthcare Conference

Mar 3, 2025, 7:30 AM EST - 6 months ago

Altimmune to Participate in the Leerink Global Healthcare Conference

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Feb 28, 2025, 2:15 PM EST - 6 months ago

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 2:24 PM EST - 6 months ago

Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Feb 27, 2025, 7:00 AM EST - 6 months ago

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Feb 25, 2025, 7:30 AM EST - 6 months ago

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

Feb 20, 2025, 7:30 AM EST - 6 months ago

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Feb 18, 2025, 5:26 AM EST - 6 months ago

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Final Trade: WST, BTC, GLD, ALT

Feb 14, 2025, 6:32 PM EST - 6 months ago

Final Trade: WST, BTC, GLD, ALT

GLD BTC WST

Drewpac
Drewpac Aug. 22 at 4:42 AM
$ALT Hi Patrick! Or should I say Bio 🥜?????
0 · Reply
Drewpac
Drewpac Aug. 22 at 4:41 AM
$ALT I got nothing to share other than I'm on the midnight train to poundtown. First stop... The 🥒 gobbler. It's gonna get nasty...
0 · Reply
BioRich
BioRich Aug. 22 at 4:33 AM
$ALT In all seriousness, what in $ALT's 48W data would take more than a week to compile, review and present? I don't see anything other than more time to try and massage data. The numbers are all in, compiled and (I believe) available for $ALT review.
1 · Reply
BioRich
BioRich Aug. 22 at 4:29 AM
$ALT Since this $ALT board seems infatuated with $VKTX and crapping all over it after its recent SP drop, can any of you explain why the SP dropped? Have any of you actually reviewed the data or just the headlines? Curious.
1 · Reply
Excessive_
Excessive_ Aug. 22 at 4:17 AM
$ALT When I see a chart like this, I get happiness thinking of the possibility that perhaps the short that is putting in all the work to push it down. Isn't the one that is doing the buying or covering at the bottom 😁 It's actually not bad, considering nearly the whole market has been crashing all week. Let's hear some good news tomorrow.
1 · Reply
Drewpac
Drewpac Aug. 22 at 4:09 AM
$ALT
0 · Reply
dachshund36
dachshund36 Aug. 22 at 3:45 AM
$ALT Could be a huge boost. We shouldn't even need a little boost, but here it is https://www.snopes.com/fact-check/ozempic-2-billion-lawsuit/
1 · Reply
ImNotLion
ImNotLion Aug. 22 at 2:58 AM
$ALT Ozempic going down in flames. 2 Billion dollar lawsuit. 1800 permanently blinded?
5 · Reply
BTECHINV
BTECHINV Aug. 22 at 2:12 AM
$ALT $XBI The higher the dose of GLP-1 and GIP, the more that stomach motility / gastric emptying is potentially impacted. Far better mechanism for a variety of reasons imo to induce thermogenic and energy expenditure metabolic effects (potent GCGR w modest GLP1 dosing). 99%+ of people have no idea about the above. The minute they realize the significance, a new global paradigm will emerge in the cultural zeitgeist. You can already imagine the articles. $NVO $PFE Disclosure: Long Altimmune (Pemvi GCGR), not medical / investment advice.
1 · Reply
Stock_Catcher
Stock_Catcher Aug. 22 at 2:06 AM
Fortune Friday Watchlist Pt. 5 $GALT $ALT $PGEN $MBOT $BSLK Squeeze Time? 🍋
1 · Reply
FlyEagleFly23
FlyEagleFly23 Aug. 22 at 1:37 AM
$ALT @Diapers_Tequila have you spoke with IR recently? Know for a while you were reaching out often.
1 · Reply
StockMktGuru
StockMktGuru Aug. 22 at 1:15 AM
$ALT Keep shorting LifeIsADream pretty soon you will change your handle to PovertyIsReal.
0 · Reply
JdNews
JdNews Aug. 22 at 1:13 AM
$ALT With Vikings loss into 50% almost wouldn’t it be amazing we get a short squeeze. To 15 again, haha
1 · Reply
Chucho64
Chucho64 Aug. 22 at 1:06 AM
$ALT With this clown's comments, my theory about short-sector coverage has changed. They have to cover the more than 25 million shares, and they're in a hurry and desperate. They'll soon be crushed.💥💥💥💥💥💥💥
1 · Reply
JdNews
JdNews Aug. 22 at 1:02 AM
$ALT Heres the thing with AltImmune, I’ve been here since they went to 25$ in I think 2018-19. I was driving to Miami when that hit. To 25$-27$ Back when Garg was promoting totally different meds. Then they bought out Spitfire and got Pemvi. 2019. Yep now it’s 2025. What’s happening I think bullish now
1 · Reply
ImNotLion
ImNotLion Aug. 22 at 1:01 AM
$ALT Word....
0 · Reply
Riveraces546
Riveraces546 Aug. 22 at 12:49 AM
$ALT $SNY huge cash reserve. 18 billion. Are they gearing up for a big transaction?
2 · Reply
Lifeisadream23
Lifeisadream23 Aug. 22 at 12:39 AM
$ALT look at bagholders cry about the truth. dont forget to google altimmune p2b mash trial and see failure. Obesity was a failure after hyping the end of p2 meeting for a year! alt can never go up if there are scammers pumping all day their lies
1 · Reply
Corpkcots
Corpkcots Aug. 22 at 12:34 AM
$ALT Still buying up shares and holding long, we will rise soon! Go ALT!
2 · Reply
MySfinktrReeks
MySfinktrReeks Aug. 22 at 12:18 AM
$ALT
0 · Reply
JdNews
JdNews Aug. 22 at 12:15 AM
$ALT just stop. You are the scammer now. Overdone.
2 · Reply
Lifeisadream23
Lifeisadream23 Aug. 21 at 11:37 PM
$ALT another scammer. altimmune tute ownership was 72% in 2024 and now its 53%! SHORT INTEREST IS GROWING THOUGH SINCE ALT IS DILUTING AT 10-20% a quarter and shorts never have to cover!
1 · Reply